MRKMerck gets the keys
Merck says the Verona Pharma deal is officially done, and Verona is now a wholly owned Merck subsidiary. Translation: Verona’s shares are off Nasdaq, and Merck just bolted a new asset onto its cardio-pulmonary portfolio.
Why this matters
The prize here is Ohtuvayre, Verona’s first-in-class COPD maintenance treatment. Merck is betting the drug can keep growing well into the next decade, which is the kind of long-tail revenue story drugmakers love almost as much as patent protection.
The investor angle
This isn’t some random tuck-in just for the trophy case. Merck is trying to deepen its pipeline in a therapeutic area where big, durable drugs can matter a lot more than one flashy quarter.
A couple things to keep in mind:
- Verona Pharma is now fully inside Merck’s house
- Verona ADSs are no longer listed or traded on Nasdaq
- Ohtuvayre already has FDA approval for COPD maintenance treatment in adults
Big picture: Merck is using M&A to keep its pipeline from running on fumes, and that’s the kind of move investors usually watch closely in Big Pharma.